Background: FOLFOX2, a bimonthly regimen of high-dose leucovorin (LV), 48-hour continuous infusion of 5-fluorouracil (5-FU) (LV-5-FU) and oxaliplatin (100 mg/m 2 ) produced a high response rate (46%; 95% confidence interval (95% CI): 31%-60%) in 5-FU pre-treated patients with metastatic colorectal cancer. In this phase II study, pre-treated patients were given a lower dose of oxaliplatin to reduce the toxic effects of the regimen.
Introduction
A bimonthly 48-hour regimen that combines high-dose leucovorin (LV) and continuous 5-fluorouracil (5-FU) infusion allowed a 4-fold dose increase of 5-FU over that of the LV-5-FU bolus regimen, with a good response rate and low toxicity [1] .
Oxaliplatin and 5-FU are synergistic in vitro and in vivo [2, 3] . In the FOLFOX2 study, 46 patients with disease progression on leucovorin and 5-FU therapy for metastatic disease were given a bimonthly regimen of high-dose LV, with 48-hour continuous infusion of 5-FU and oxaliplatin at 100 mg/m 2 . The overall response rate was 46% and, from the start of FOLFOX2, the median progression-free survival was seven months and median survival 17 months. The response rate was 45% for 22 patients with documented progression given the same bimonthly schedule of LV-5-FU as that used in FOL-FOX2 (refractory patients). Overall, 21 patients (46%) experienced WHO grade 3-4 toxicity: peripheral neuropathy 9% (23% grade 2), neutropenia 39%, thrombocytopenia 11%, mucositis 13% and diarrhea 9%.
In the present study (FOLFOX3), in an attempt to lower toxicity and standardize the oxaliplatin dose intensity with that recommended in a single-agent phase II trial (130 mg/m 2 every three weeks) [4] , we treated refractory patients with oxaliplatin at 85 mg/m 2 every two weeks in conjunction with LV-5-FU.
Patients and methods
The patients enrolled between January and November 1995 were 18-75 years old, and had histologically confirmed adenocarcinoma of the colon or the rectum, bidimensionally measurable metastases evaluated by computed tomography scan (CT scan) prior to initiation of therapy, and WHO performance status (PS) < 2. The patient characteristics are listed in Table 1 . Required laboratory parameters included: neutrophils > 1,500/ul, platelets > 100,000/ul, serum creatinine level < 200 nmol/1 and serum alkaline phosphatases < 3 times the upper limit of the normal range. For inclusion, patients had to have documented progression as defined by WHO ( > 2 5 % increase of assessable disease or the appearance of new neoplastic lesion) while receiving bimonthly LV-5-FU (LV: 500 mg/m 2 , 5-FU: 1.5-2 g/m 2 /22 hours, days 1-2, every two weeks) ± interferon-oc [1, 5] , With this previous chemotherapy, 12 patients had a partial response (40%), 13 patients were stable (43%) and five patients directly progressed (17%). The time lapse between the last 5-FU infusion and progression assessment was < 3 weeks for all patients. Informed consent was obtained from all patients. FOLFOX3 consisted of LV (500 mg/m 2 ) as a two-hour infusion followed by a 22-hour infusion of 5-FU (1.5 g/m 2 /22 hour) for two consecutive days. Oxaliplatin (85 mg/m 2 ) was given as a two-hour infusion (day 1) during LV infusion but without prior mixing. For the third and subsequent cycles, the 5-FU dose was increased to 2 g/m 2 /22 hour when maximal toxicity was below WHO grade 2. Cycles were repeated at two-week intervals. This regimen was discontinued at 17 (57) 13 (43) 24 (80) 8 (27) 4 (13) 6 (20) 20 (67) 7 (23) 3 (10) 17 (57) 9 (30) 4 (13) 18 (60) 12 (40) 17 (57) 13 (43) 4 (13) 26 (87) 25 (83) 5 (17) 24 (80) 6(20) 27 (90) 3 (10) a LV-5-FU: two-day bimonthly regimen of leucovorin and 5-fluorouracil ± a-interferon [1, 5] .
disease progression or instances of unacceptable toxicity. When WHO grade 1 peripheral neuropathy occurred after six cycles, oxaliplatin was given only every two cycles and when WHO neurological toxicity was > grade 2 (pain or functional impairment), oxaliplatin was discontinued. Before each cycle, patients underwent a clinical examination, and blood cell counts were assessed. CT scan evaluated the antitumor response every six cycles. Hepatic function and carcinoembryogenic antigen (CEA) were assessed every six cycles.
Results
The 30 patients included in the study were evaluated for response and toxicity. Six patients achieved partial responses. The overall response rate (WHO definition) was 20% (95% CI: 8%-39%). Fifteen patients had disease Figure 1 . Survival (bold line) and progression-free survival (thin line) observed with FOLFOX3 for refractory advanced colorectal cancer. 
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stabilization (50%) and nine progressed (30%). Median progression-free survival was 26 weeks (range 12-70), median survival was 57 weeks from the start of FOL-FOX3 ( Figure 1 ) and the median durations of response and stabilization were, respectively, 37 and 27 weeks. Pre-existing symptoms regressed or disappeared in five of 12 patients who were symptomatic at study entry. PS improved in five of 13 with PS ^ 1 at inclusion. A weight increase ^2 kg was observed in only two patients. Of the 26 patients with elevated CEA levels at the start of therapy, nine (35%) experienced decreases of ^ 50%. The frequencies of the main toxicities/patient based on the analyses of 284 cycles given to the 30 patients are reported in Table 2 . The median number of cycles/ patient was 9.5 (range 5-18). Maximal toxicity/patient grade 3 was non-febrile neutropenia 6 (20%), thrombocytopenia 4 (13%), anemia 1 (3%), allergy 2 (7%). Eight patients suffered grade 3-4 toxicity (27%). For seven patients, the 5-FU dose was lowered to < 1.5 g/m 2 /22 hours, days 1-2, mainly for hematological toxicity. Two patients experienced acute episodes of laryngospasms, without recurrence when the full oxaliplatin dose was subsequently given in a six-hour infusion. Four patients had severe sensory neuropathy (WHO grade 2: 13%) consisting of functional impairment due to a loss of sensitivity in the fingertips or soles of the feet. Five patients had to stop treatment prematurely: the four sensory neuropathy patients after 11-15 cycles, with a median time to complete (n = 2) or partial neurological recovery (n = 2) of 10 months after discontinuation of oxaliplatin; one patient after an anaphylactic reaction to oxaliplatin which fully regressed, but the drug was never reintroduced.
dose intensity > 85 mg/m 2 every 14 days in combination with LV and a lower dose of 5-FU. The results of this trial suggest that combination of a lower dose of 5-FU with oxaliplatin may limit hematological toxicity and allow to increase the oxaliplatin dose intensity. This may help further to define the optimum dose schedule for oxaliplatin.
Discussion
Oxaliplatin used alone at a dose of 130 mg/m 2 every 21 days in patients with metastatic colorectal cancer is an active agent. In first-line chemotherapy, the overall response rate was between 12% and 20% with a four-month median progression-free survival and a 14.5-month median overall survival [6] . In patients resistant to LV-5-FU, oxaliplatin yielded a reproducible 10% response rate when administered every three weeks at 130 g/m 2 [4] . Clinical studies of second-line therapy consisting of oxaliplatin in combination with LV-5-FU have shown a better response rate than oxaliplatin alone [3, 7, 8] .
FOLFOX3, given to patients with documented progression while receiving bimonthly LV-5-FU (refractory metastatic colorectal cancer) had antitumor activity, with an acceptable tolerance. One of the severe drugrelated toxic side effect was one episode of anaphylaxis that occurred several minutes into the 8th cycle of oxaliplatin perfusion, when the patient complained of a burning sensation of the face with flush, shortness of breath and a drop in systolic blood pressure. The patient recovered fully after the incident and the drug was not reintroduced. Only six patients had non-febrile neutropenia grade 3-4, without hemorrhage. The most common adverse event was sensory neuropathy (90%), in terms of paresthesias sometimes associated with laryngopharyngeal dysesthesias, in four instances with functional impairment necessitating oxaliplatin withdrawal. Most patients received prophylaxis with a serotonin antagonist, and gastrointestinal toxicity was moderate. As compared to the FOLFOX2 regimen [3] , the response rate was lower (20% vs. 46%) with similar progression-free survival (six vs. seven months) and a lower toxicity rate (sensory neuropathy ^ WHO grade 1: 13% vs. 33%; grade 3-4 neutropenia: 20% vs. 40%). These could be due to the lower oxaliplatin dose or to patient selection. In these two small studies, these differences are not presumably statistically significant and require further data to define the optimum dose schedule for oxaliplatin with LV-5-FU. Preliminary results of a multicenter study conducted in France with FOLFOX3 included a 25% response rate [8] . Hematological toxicity is a recognized side effect of 5-FU treatment and can usually be controlled with dose reduction. Ongoing studies (FOLFOX6 and 7) are evaluating an oxaliplatin
